1-20 of 98
keshu zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Free
Keshu Zhou, Tingyu Wang, Ting Niu, Meifang Zheng, Jie Jin, Yang Liang, Rui Huang, Shuangnian Xu, Jianhua Qu, Guohui Cui, Fei Li, Yiming Luo, Ru Feng, Wenzheng Yu, Caixia Li, Zhiling Yan, Xin Zhou, Suijing Wu, Lihong Liu, Yinghua Geng, Jishi Wang, Sujun Gao, Jianfei Fu, Xiaoping Zhang, Chunyan Ji, Qianqian Xiang, Xiongpeng Zhu, Yajing Xu, Li'e Lin, Xiaoyu Zhu, Yuping Zhong, Hongling Peng, Ying Zhao, Hui Zeng, Zhao Wang, Rong Fu, Wenbin Qian, Yingmin Liang, Xiaobing Huang, Yajun Li, Min Yu, Zi Chen, Lei Wang, Lichuang Men, Zhiyan Liang, Shan Zeng, Baoer Lu, Yifan Zhai, Jianyong Li
Journal: Blood
Blood (2025) 146 (Supplement 1): 88.
https://doi.org/10.1182/blood-2025-88
Published: 2025
Journal Articles

Efficacy and safety of zanubrutinib-containing regimens in patients with newly diagnosed Mantle Cell Lymphoma: Interim results from a Phase II investigator-initiated study

Free
Qing Zhang, Yi Wu, Xueli Jiao, Qinglan Zhang, Xingchen Liu, Fenghua Gao, Hao Guo, Zhanfang Wang, quande Lin, Shuli Guo, Fengkuan Yu, Jianwei Du, Lihua Dong, Hu Zhou, Ping Wang, Yuqing Chen, Yan Huang, Yan Zhao, Hongmian Zhao, Xiujuan Zhao, Keshu Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 1823.
https://doi.org/10.1182/blood-2025-1823
Published: 2025
Journal Articles

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma

Free
Zhijuan Lin, Long Liu, Manman Deng, Xingxing Yu, Yan Hong, Hua Wang, Keshu Zhou, Shaojie Wu, Ting-Bo Liu, Na Qin, Rui Su, Zhifeng Li, Bing Xu
Journal: Blood
Blood (2025) 146 (Supplement 1): 1818.
https://doi.org/10.1182/blood-2025-1818
Published: 2025
Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Free
Peihua Lu, Yong-xian Hu, Xian Zhang, Junfang Yang, Xiaoyu Zhu, Ying Wang, Keshu Zhou, Sanbin Wang, Jiang Cao, Heng Mei, Kai Hu, Yong Yu, Yali Zhou, Eileen McNulty, Ming Gao, Maria Delrosario, Wengang Ge, Yajin Ni, Jiangtao Ren, Jan Davidson-Moncada, He Huang
Journal: Blood
Blood (2025) 146 (Supplement 1): 1042.
https://doi.org/10.1182/blood-2025-1042
Published: 2025
Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Free
Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao
Journal: Blood
Blood (2025) 146 (Supplement 1): 5415.
https://doi.org/10.1182/blood-2025-5415
Published: 2025
Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Free
Zhengming Jin, Huilai Zhang, Changju Qu, Wenbin Qian, Keshu Zhou, Wenrong Huang, Bing Xu, Hongmei Jing, Wenyu Li, Kang Yu, Ting Niu, Wei LIU, Xi Zhang, Yuhua Li, Huiqiang Huang, Haiyan Yang, Hua Yang, Wei Xu, Jinghua Zhao, Depei Wu
Journal: Blood
Blood (2025) 146 (Supplement 1): 1796.
https://doi.org/10.1182/blood-2025-1796
Published: 2025
Journal Articles

First-line selinexor plus R-CHOP for high-risk GCB-subtype diffuse large B-cell lymphoma: A multi-center, single-arm, Phase II trial

Free
Hang Yang, Peng SUN, Panpan LIU, Yu Wang, Hui Zhou, Ying Lu, Lu Zhang, Keshu Zhou, Zhiming Li
Journal: Blood
Blood (2025) 146 (Supplement 1): 1922.
https://doi.org/10.1182/blood-2025-1922
Published: 2025
Journal Articles

The preliminary results of MRG001-C002: A phase II Study of MRG001 combined with Orelabrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)

Free
Keshu Zhou, Xingchen Liu, Xueli Jiao, Qing Zhang, xu Ji, Qianying Pan, Kai Hu, Bian Wei, Lin Chen, Fenghua Gao, Minghui Li, Quande Lin, Ruihua Mi, Fengdi Wang, Haiying Wang, Qinglan Zhang, Lihua Dong
Journal: Blood
Blood (2025) 146 (Supplement 1): 1914.
https://doi.org/10.1182/blood-2025-1914
Published: 2025
Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Free
Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li
Journal: Blood
Blood (2025) 146 (Supplement 1): 1910.
https://doi.org/10.1182/blood-2025-1910
Published: 2025
Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Free
Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song
Journal: Blood
Blood (2025) 146 (Supplement 1): 5368.
https://doi.org/10.1182/blood-2025-5368
Published: 2025
Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Free
Yuqin Song, Qingqing Cai, Keshu Zhou, Zhengming Jin, Ming Jiang, Xiuhua Sun, Lei Zhang, Haiyan Yang, Lanfang Li, Kaiyang Ding, Junyuan Qi, MIN Zhou, Hongmei Jing, Wei Yang, Hui Zhou, Jun Ma, Zhigang Peng, Wei Xu, Li Yu, Yuankai Shi, Guohui Cui, Zheng Wang, Nawei Liu, Yejiang Lou, Yue Shen, Yi Chen, Fenlai Tan, Jun Zhu
Journal: Blood
Blood (2025) 146 (Supplement 1): 3896.
https://doi.org/10.1182/blood-2025-3896
Published: 2025
Journal Articles

Thyroid diffuse large B-cell lymphoma in China: Multicenter study of diagnosis, clinical features, treatment efficacy, prognostic factors, and genomic alterations

Free
Fei Li, Hao Sun, Guohui Cui, Ou Bai, Shenmiao Yang, zunmin zhu, Peiqi Zhao, Keqian Shi, keshu zhou, Siguo Hao, Jia Wei, Hui Zhou, Kaiyang Ding, Xiangxiang Zhou, Honghui Huang, Ting-Bo Liu, fan zhou, Bing Xu, Aibin Liang, Shuye Wang, Ru Feng, Wenyu Shi, Wei Li Zhao
Journal: Blood
Blood (2025) 146 (Supplement 1): 1902.
https://doi.org/10.1182/blood-2025-1902
Published: 2025
Journal Articles

Efficacy and safety of polatuzumab vedotin-based regimens for elderly/frail DLBCL patients: A real-world study

Free
Xingchen Liu, Qing Zhang, Qianying Pan, Xueli Jiao, Fenghua Gao, Lihua Dong, Zhihua Yao, Keshu Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 5470.
https://doi.org/10.1182/blood-2025-5470
Published: 2025
Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Free
Theodoros Vassilakopoulos, Javier Munoz, Huiqiang Huang, Ichiro Kawashima, Sung Yong Oh, Wojciech Jurczak, Juan Miguel Bergua Burgues, Ou Bai, Alejandro Berkovits, Keshu Zhou, Marc Hoffmann, Jason Westin, Maria Bouzani, Michal Kwiatek, Tai-Chung Huang, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Serena Perna, Grzegorz Nowakowski
Journal: Blood
Blood (2025) 146 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2025-3704
Published: 2025
Journal Articles

Phase 1/2 studies of DZD8586 in CLL/SLL patients after COVALENT and non-COVALENT BTK inhibitors and BTK degraders – extended follow-up report

Free
Keshu Zhou, Tingyu Wang, Wei Yang, Jian-Qing Mi, Sujun Gao, Huayuan Zhu, Xutao Guo, Kaiyang Ding, Ying Xiang, Huili Cai, Guohui Cui, Yun Zhuang, Hongmei Jing, Liping Su, Rui Huang, Lihua Qiu, Mark Geyer, Wuhan Hui, Geoffrey Chong, Meifang Zheng, Yi Wang, Ying Li, Ke Fang, Chan Cheah, Jianyong Li
Journal: Blood
Blood (2025) 146 (Supplement 1): 3889.
https://doi.org/10.1182/blood-2025-3889
Published: 2025
Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Free
Yuqin Song, Qingqing Cai, Keshu Zhou, Zhengming Jin, Ming Jiang, Xiuhua Sun, Lei Zhang, Haiyan Yang, Lanfang Li, Kaiyang Ding, Junyuan Qi, MIN Zhou, Hongmei Jing, Wei Yang, Hui Zhou, Jun Ma, Zhigang Peng, Wei Xu, Yuankai Shi, Guohui Cui, Zheng Wang, Nawei Liu, Yejiang Lou, Yue Shen, Yi Chen, Fenlai Tan, Jun Zhu
Journal: Blood
Blood (2025) 146 (Supplement 1): 3587.
https://doi.org/10.1182/blood-2025-3587
Published: 2025
Journal Articles

Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT Induces Durable Remissions in PD-(L)1 inhibitor-resistant Refractory/relapsed classical Hodgkin lymphoma: A single-center, long-term study

Free
Xingchen Liu, Qing Zhang, Hao Guo, Qianying Pan, Keshu Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 1847.
https://doi.org/10.1182/blood-2025-1847
Published: 2025
Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Free
Keshu Zhou, Liqun Zou, Zhiming Li, Shuhua Yi, Yajun Li, Jie Jin, Zengjun Li, Li Wang, Larysa Nogaieva, Guohui Cui, Hongxiang Wang, Jian Ge, Fei Li, Zhongxing Jiang, Xiuhua Sun, Xiaohan Li, Chen Luo, Weige Wang, Renbin Zhao, Lugui Qiu
Journal: Blood
Blood (2025) 146 (Supplement 1): 887.
https://doi.org/10.1182/blood-2025-887
Published: 2025
Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Free
Yuqin Song, Qingqing Cai, Xiaoqiong Tang, Keshu Zhou, Lihong Liu, Zhigang Peng, Xiaojing Yan, Kaiyang Ding, Jianzhen Shen, Huijing Wu, Jie Cui, Hui Zhou, Jianqiu Wu, Hongmei Jing, Ming Jiang, Xiuhua Sun, Yu Yang, Kang Yu, Wei Yang, Zhifeng Li, Zhengming Jin, Shuhua Yi, Fei Li, Guowu Wu, Xiaolei Wei, Gaoxiang Wang, Yudan Wu, Ningjing Lin, Fenlai Tan, Yue Shen, Yejiang Lou, Xiang Xiao, Jun Zhu
Journal: Blood
Blood (2025) 146 (Supplement 1): 886.
https://doi.org/10.1182/blood-2025-886
Published: 2025
Journal Articles

Targeting SF3B1 disrupts CLL cell survival via pfkfb-mediated glycolytic dependency and confers vulnerability to BTK inhibition

Free
Yongyi Yuan, Hao Guo, Siming Zheng, Keshu Zhou
Journal: Blood
Blood (2025) 146 (Supplement 1): 7409.
https://doi.org/10.1182/blood-2025-7409
Published: 2025